TOPICS
Link Building for Biotech & Pharma
DIRECT ANSWER
Link building is the practice of acquiring hyperlinks from external websites pointing to your own, with the goal of improving search engine authority and rankings. Search engines use links as votes of credibility — a link from a relevant, high-authority domain signals to Google that your content is trustworthy and worth ranking. Quantity matters less than the relevance and authority of linking domains. For Biotech & Pharma companies, this matters because Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch.
What link building means for Biotech & Pharma
The MLR bottleneck is the defining pain. Position AI-CMO as a pre-MLR content acceleration layer — draft variations auto-generated with reference tagging to approved label language, so reviewers approve faster. Integration with Veeva Vault PromoMats is table stakes for enterprise deals. Secondary angle: omnichannel orchestration for HCP journeys that synchronize rep calls, emails, and event invites without manual coordination.
For Biotech & Pharma teams the relevant marketing pains are: Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch; HCP segmentation is done manually in Excel — field reps don't have actionable, data-driven targeting for their territories; Congress season (ASCO, ADA, ACC) creates content demand spikes that small medical affairs teams cannot absorb; Patient support programs are marketed reactively rather than through proactive lifecycle journeys; KOL engagement tracking is scattered across MSL notes, CRM fields, and email threads with no unified view; Brand teams in different therapeutic areas duplicate research and creative work with no shared asset library. FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute
Link Quality vs. Link Quantity
Domain Rating (Ahrefs) and Domain Authority (Moz) are commonly used proxies for a linking domain's authority. A single link from a respected industry publication can contribute more ranking power than hundreds of links from low-authority directories or blog networks. The relevance of the linking page's topic to your content matters alongside raw authority — a link from a finance publication to a fintech article carries more signal than a link from an unrelated niche.
Toxic links — from link farms, paid link networks, or irrelevant low-quality sites — can harm rankings or trigger manual penalties. Audit your backlink profile quarterly using tools like Google Search Console, Ahrefs, or Semrush. Disavow links only when there is clear evidence of a pattern of manipulative links; over-disavowing clean links is also a risk.
Running link building for Biotech & Pharma with CoMo
CoMo's agents apply link building across HCP email, med-ed portals, LinkedIn, congresses/events, speaker programs, rep-triggered digital, patient advocacy partnerships for Biotech & Pharma companies — tuned to VP Commercial Marketing at mid-size pharma; Director of Marketing Excellence at specialty biotech; Head of Omnichannel at large pharma and run under your approval, alongside every other marketing function.
FAQ
Link Building for Biotech & Pharma — common questions
Is guest posting still an effective link building tactic?
On editorially selective, relevant publications, yes. Guest posting on low-quality sites that accept any submission for a fee is a link scheme Google has actively targeted. The test is editorial standards: if a publication would not publish your piece without a backlink exchange, the link has limited value and carries penalty risk.
How does link building differ for Biotech & Pharma companies?
The fundamentals are the same, but Biotech & Pharma marketing carries specific constraints — Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch and FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute. CoMo adapts execution to that context automatically.
RELATED
BUILT BY COMO'S AGENTS
This page was written by CoMo — the autonomous CMO.
CoMo runs every channel of your marketing on your live data. See it work on your brand.